Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.
FDA application actionJuly 18, 2023
Omeprazole
Approved submission · SUPPL 25
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 18, 2023
Omeprazole
Approved submission · SUPPL 20
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 18, 2023
Omeprazole
Approved submission · SUPPL 9
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 17, 2023
hydrochlorothiazide
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 17, 2023
hydrochlorothiazide
Approved submission · SUPPL 5
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 17, 2023
Cyclophosphamide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 12, 2023
hydrochlorothiazide
Approved submission · SUPPL 7
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 12, 2023
hydrochlorothiazide
Approved submission · SUPPL 5
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 12, 2023
hydrochlorothiazide
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 12, 2023
hydrochlorothiazide
Approved submission · SUPPL 7
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 10, 2023
liraglutide
Approved submission · SUPPL 21
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 6, 2023
Naltrexone
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 5, 2023
liraglutide
Approved submission · SUPPL 39
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 27, 2023
Cyclophosphamide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 23, 2023
Oxaliplatin
Approved submission · SUPPL 24
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 22, 2023
Everolimus
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 22, 2023
Everolimus
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 22, 2023
Everolimus
Approved submission · SUPPL 9
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 12, 2023
Omeprazole
Approved submission · SUPPL 7
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 7, 2023
hydrochlorothiazide
Approved submission · SUPPL 28
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 7, 2023
hydrochlorothiazide
Approved submission · SUPPL 37
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 7, 2023
hydrochlorothiazide
Approved submission · SUPPL 23
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 7, 2023
Cyclophosphamide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 2, 2023
hydrochlorothiazide
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →